ArticleEuropean archives of psychiatry and clinical neuroscience2026
Upregulation of circSUCO22-20 in schizophrenia: clinical correlation with systemic inflammation and in vitro pro-apoptotic mechanisms.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEmerging evidence links dysregulation of circular RNAs (circRNAs) to neuropsychiatric disorders, but their pathophysiological roles in schizophrenia (SCZ) remain unclear. We investigated the clinical significance, biological function, and underlying mechanisms of circSUCO22-20 in SCZ.
methodsPrevious whole-transcriptome sequencing identified circSUCO22-20 as differentially expressed in SCZ. Sanger sequencing and RNase R digestion confirmed its covalently closed-loop structure. RT-qPCR validation was performed in 158 patients with SCZ and 158 healthy controls. Associations with Positive and Negative Syndrome Scale (PANSS) scores and systemic inflammatory indicators were assessed using Pearson correlation and restricted cubic spline (RCS) analyses. Cell Counting Kit-8 (CCK-8) and apoptosis assays were used to detect the viability and apoptosis of MK-801 (dizocilpine)-treated SH-SY5Y cells. A dual-luciferase assay was used to confirm the binding relationships among circSUCO22-20, hsa-miR-3913-3p, and SLC7A11. The GSE25673 dataset (iPSC-derived neurons) was analyzed for downstream validation.
resultscircSUCO22-20 was significantly upregulated in both patients with SCZ and MK-801-treated SH-SY5Y cells. RCS analysis revealed significant non-linear dose-response correlations between circSUCO22-20 and white blood cell (WBC) count (Poverall = 0.035, Pnon-linear = 0.011), neutrophil count (NEUT) (Poverall = 0.018, Pnon-linear = 0.005), and lymphocyte percentage (LYMPH%) (Poverall = 0.031, Pnon-linear = 0.029). Knockdown restored cell viability and attenuated apoptosis, whereas overexpression exacerbated neuronal injury. Mechanistically, circSUCO22-20 acted as a ceRNA by sponging hsa-miR-3913-3p, thereby modulating SLC7A11 expression. Bioinformatic analysis confirmed SLC7A11 upregulation in SCZ iPSC-derived neurons.
conclusioncircSUCO22-20 is upregulated in SCZ and correlates with systemic inflammation. By modulating the hsa-miR-3913-3p/SLC7A11 axis, it exacerbates neuronal apoptosis, supporting its potential as a diagnostic biomarker and therapeutic target for SCZ.
Indexed as
Identifiers
42608582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.